Tandem Diabetes Care (NSDQ:TNDM) today shared real-world data on its t:slim X2 insulin pump with Control-IQ advanced hybrid closed-loop technology.
Presenting at the 14th International Conference on Advanced Technologies and Treatments for Diabetes (ATTD), the company touted immediate and sustained improvements in time-in-range (TIR) observed in more than 9,000 people with diabetes using the system for 12 months.
Get the full story at our sister site, Drug Delivery Business News.
Barclays analysis projects that medtech might be on its way to a stretch of “outperformance” even in the wake of the COVID-19 pandemic.
According to SeekingAlpha, the report cited eight reasons that make the investment bank bullish on the industry in the coming years, starting with what it calls “robust innovation.”
On top of the evolving innovation in medtech, Barclays expects the canceled procedures of 2020 (as a result of COVID-19) to return, while new technology could increase diagnoses.
Direct-to-consumer advertising, a potential return to “normality” in a post-pandemic scape, surveys indicating a resurgence in elective surgeries, healthy balance sheets and an aging population as a tailwind round out the reasons why Barclays expects success for medtech over the next several years.
Medtech companies that Barclays stands “overweight on” include Abbott (26.72% upside), Boston Scientific (18.55% ups…
Tandem Diabetes Care (NSDQ:TNDM) shares rose after hours today on first-quarter results that beat the consensus forecast.
The San Diego-based company posted losses of -$5 million, or -8¢ per share, on sales of $141 million for the three months ended March 31, 2021, for a 66.1% bottom-line gain on sales growth of 44%.
Get the full story at our sister site, Drug Delivery Business News.
CeQur announced today that it closed an oversubscribed equity financing round with proceeds of $115 million.
Lucerne, Switzerland/Marlborough, Mass.–based CeQur said in a news release that it plans to use the funds to advance the commercial plans for the CeQur Simplicity wearable insulin delivery device. The company’s plans include market development, a phased commercial launch with a limited market release in 2021 and the scale-up of high-volume manufacturing.
Get the full story at our sister site, Drug Delivery Business News.
Tandem Diabetes Care (NSDQ:TNDM) announced today that it appointed Dr. Jordan Pinsker as its VP & medical director.
The San Diego-based insulin delivery technology developer’s appointment of Pinsker will be made effective on April 26, 2021, according to a news release.
Get the full story at our sister site, Drug Delivery Business News.
The drug delivery space has seen plenty of innovation over the years and there are no signs of that slowing down any time soon.
Improvements upon established technologies like insulin delivery devices and inhalers have been presented by some, while others have unlocked new ways of delivering drugs through a variety of means.
Among the best innovations in the space are some of the heavy-hitting companies, like Medtronic and Tandem Diabetes Care. Some up-and-comers are beginning to make waves, too, while research continues to uncover new ways to deliver therapeutics.
Here are eight types of drug delivery innovations you should know:
Next>>The drug delivery space has seen plenty of innovation over the years and there are no signs of that slowing down any time soon.
Improvements upon established technologies like insulin delivery devices and inhalers have been presented by some, while others have unlocked new ways of delivering drugs through a variety of means.
Among the best innovations in the space are some of the heavy-hitting companies, like Medtronic and Tandem Diabetes Care. Some up-and-comers are beginning to make waves, too, while research continues to uncover new ways to deliver therapeutics.
Here are eight types of drug delivery innovations you should know:
Next>>The drug delivery space has seen plenty of innovation over the years and there are no signs of that slowing down any time soon.
Improvements upon established technologies like insulin delivery devices and inhalers have been presented by some, while others have unlocked new ways of delivering drugs through a variety of means.
Among the best innovations in the space are some of the heavy-hitting companies, like Medtronic and Tandem Diabetes Care. Some up-and-comers are beginning to make waves, too, while research continues to uncover new ways to deliver therapeutics.
Here are eight types of drug delivery innovations you should know:
Next>>Tandem Diabetes Care (NSDQ:TNDM) shares soared after hours today on fourth-quarter results that topped the consensus forecast.
Shares of TNDM were up 12.9% at $103.04 per share after the market closed. MassDevice’s MedTech 100 Index — which includes stocks of the world’s largest medical device companies — was up 0.8%.
Get the full story at our sister site, Drug Delivery Business News.
Despite a minor regression week-over-week, the medtech industry’s stocks hit another milestone as the COVID-19 rebound remains in progress.
MassDevice’s MedTech 100 Index — which includes stocks of the world’s largest medical device companies — sat at 89.01 points at the end of last week (July 31). Overall, medtech stocks saw a -0.3% increase from the 89.29-point total at the same time a week prior (July 24).
On July 30, the index reached 90.37 points, marking its highest point since that pre-pandemic high, with the previous mid-pandemic high (90.11) coming last week.
The most recent high mark represents just a -2.1% dip from the Feb. 19 high point of 92.32, marking the smallest margin of decline over the past five months.
Meanwhile, the S&P 500 Index saw a 1.7% increase from July 24 to July 31, and the Dow Jones Index posted a -0.2% drop over the same period of time.
Medtech’s lowest point during the COVID-19 pandemic remains at …
Tandem Diabetes Care (NSDQ:TNDM) posted Street-beating second-quarter sales and missed badly on earnings, but reinstated its earlier full-year 2020 guidance.
The San Diego-based company — maker of insulin pumps and other diabetes management devices — reported a loss of -$27.1 million or -0.45¢ per share, on sales of $109.2 million for the three months ended June 30, 2020, for a bottom-line loss of -17% compared with Q2 2019.
Get the full story on our sister site, MassDevice.
Tandem Diabetes Care (NSDQ:TNDM) posted Street-beating second-quarter sales and missed badly on earnings, but reinstated its earlier full-year 2020 guidance.
The San Diego-based company — maker of insulin pumps and other diabetes management devices — reported a loss of -$27.1 million or -0.45¢ per share, on sales of $109.2 million for the three months ended June 30, 2020, for a bottom-line loss of -17% compared with Q2 2019.
Tandem pegged the losses largely to interest expenses and charges reflecting changes in fair value for certain outstanding warrants.
Earnings per share were 21¢ behind The Street, where analysts were looking for sales of $87.15 million.
Domestic insulin pump shipments increased 15% to 14,735 in the second quarter of 2020, up from 12,799 pumps Q2 2019. Domestic sales were $89.3 million, or 27% higher than the $70.4 million in the second quarter of 2019. International pump shipments fell by 53% percent to 3,952 in the second qua…